Company

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken
Finanical ReportsNovo Nordisk

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Novo Nordisk A/S (NYSE: NVO) reported third‑quarter 2026 revenue of DKK 79.20 billion (USD 12.03 billion), up 6% in Danish kroner and 4% at constant exchange rates (CER), as obesity‑drug…

Sanofi's Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps

Sanofi’s Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps

Bayer's Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Bayer’s Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China
CancerMabwell Bioscience

Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China

Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India
CancerFosun Pharmaceutical

Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India

Sanofi's Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment
NASDAQ: SNYRare / orphan disease drugs

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer
ADC / XDCBio-Thera Solutions

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer

Show More